Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group
Pasquale Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Comella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), G. Frasci(Radiation Oncology Institute), Vito Lorusso(Istituto Tumori Bari), Gaetano Di Rienzo(Medical Center Hospital), G.P. Nicolella(Radiation Oncology Institute), R Cioffi(Medical Center Hospital), Carmen Pacilio(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michèle Natale(Medical Center Hospital), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Luigi Manzione, Andrea Bianco(Keele University), Giuseppe De Cataldis(Radiation Oncology Institute), Nicola Panza(Radiation Oncology Institute), Franco Carpagnano(Radiation Oncology Institute), Mario De Lena(Radiation Oncology Institute), Luigi Maiorino(Medical Center Hospital)
Cited by 73
Related Papers
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452
Polymorphism at the Glutathione <i>S</i> -transferase GSTP1 Locus: A New Marker for Bronchial Hyperresponsiveness and Asthma
|American Journal of Respiratory and Critical Care Medicine|2000|263
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Adiponectin as Link Factor between Adipose Tissue and Cancer
|International Journal of Molecular Sciences|2019|138
Lapatinib in breast cancer
|Annals of Oncology|2007|129